The disposition of albumin in humans has been studied for more than one hundred years, but it was not until the 1980s and 1990s that the disposition characteristics of albumin were studied in subsets of critically ill patients with increased vascular permeability not complicated by sequestration of albumin in wounds or losses of albumin from bleeding or injured sites. Knowledge of how albumin disposition might vary in subsets of critically ill patients is important, particularly for crystalloid-albumin comparative trials based on resuscitation endpoints related to plasma expansion. The purpose of this critical review is to analyse studies evaluating the disposition of albumin in critically ill patients and to compare the findings to studies evaluating the disposition of albumin in healthy subjects and less severely ill patients. A secondary objective is to determine whether the disposition of albumin differs in subsets of critically ill patients.
| WHAT IS K NOWN AND OBJEC TIVE
The disposition of albumin in humans has been studied for more than one hundred years, but it was not until the 1980s and 1990s that the disposition characteristics of albumin were studied in subsets of critically ill patients with increased vascular permeability not complicated by sequestration of albumin in wounds or losses of albumin from bleeding or injured sites. Knowledge of how albumin disposition might vary in subsets of critically ill patients is important, particularly for crystalloid-albumin comparative trials based on resuscitation endpoints related to plasma expansion. The purpose of this critical review is to analyse studies evaluating the disposition of albumin in critically ill patients and to compare the findings to studies evaluating the disposition of albumin in healthy subjects and less severely ill patients. A secondary objective is to determine whether the disposition of albumin differs in subsets of critically ill patients.
| COMMENT
A search strategy was devised with the assistance of a medical librarian with expertise in systematic reviews. The electronic bibliographic databases searched were as follows: PubMed and EMBASE.
Bibliographies of retrieved articles were used to locate additional relevant articles using the citation index Scopus in addition to searching the bibliographic databases PubMed and Embase. The PubMed search retrieved 1828 articles and the EMBASE search retrieved 484 articles to be screened for inclusion. Only 16 studies were found to be eligible for qualitative synthesis. Given the limited number and noncomparative nature of the studies included, no quantitative analysis or meta-analysis was possible.
The dispositional characteristics of albumin reported in older studies involving noncritically ill patients are important to give context to the findings from more recent studies evaluating the disposition of albumin in critically ill patients. The earliest studies examining the disposition of albumin and its effects on other solutes were conducted in increased plasma volume by an average of 16 mL using before-after haematocrit measurements to determine plasma volumes. 8 The earliest studies investigating the disposition of albumin in normal volunteers were performed in the early 1950s using biosynthesized tracers (S 35 or N 15 ) and radiolabelled albumin (I 131 ). The terminal half-life of albumin in these healthy subjects ranged from 10 to 20 days depending on the method used. The variability in halflife was thought to be due to inadequate blood sampling, as well as reutilization of biosynthesized isotope after albumin/isotope degradation, a problem not likely to occur with the I 131 -labelled albumin.
Subsequently, from mid-1950 to the 1960s, radiolabelled albumin was used to study the disposition of albumin in healthy subjects, patients undergoing surgery and patients with thermal injuries.
In one of the early and important trials using radiolabelled albu- By the early 1960s, it was realized that different assumptions were required for the different forms of data analysis associated with blood sampling after radiolabelled albumin injections. 13 In one study of hospitalized patients with controlled, chronic disease states but no heart, liver or renal disease, a single 10-minute sample gave a blood volume estimation within approximately 5% of several samples drawn over 10 minutes with extrapolation to time zero. 14 This single sampling technique was adequate because of rapid mixing and slow leakage of the radiolabelled albumin from the intravascular to extravascular compartment. 15 Furthermore, in healthy subjects or relatively healthy patients, once the albumin had transferred to the extravascular compartment, the final elimination phase of albumin was characterized by a linear degradation curve that could be used to calculate terminal half-life. However, the latter assumption of steady state conditions for terminal half-life determination may be violated in more severely stressed or ill populations.
For example, in a study involving blood sampling over a 2-week period following radiolabelled albumin injections, normal subjects (n = 8) had a mean terminal half-life of 11 days compared to 4.6 to 7.3 days in patients (n = 10) undergoing various types of surgery. The authors recognized the lack of steady state conditions in the surgical patients and realized that plasma disappearance of albumin was not necessarily reflective of degradation (hence the use of the term "apparent half-times" in the published findings). 16 This was confirmed by studies evaluating organ-specific distribution of radiolabelled albumin. For example, when Rothschild et al studied two patients who died of complications of heart failure, 50% of extravascular albumin was in skin or muscle and another 25%-30% was in large thoracic or abdominal viscera.
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In noncirrhotic patients with chronic disease states (hypertension, heart failure), transcapillary albumin escape is increased, but the extravascular albumin mass is constant due to concomitant increased lymphatic return of albumin to plasma. 18, 19 However, in patients who undergo major surgical procedures or have severe forms of injury or infection, this increase in lymphatic albumin return is often unable to keep up with the transcapillary losses found. [20] [21] [22] [23] Evaluations of the disposition of albumin in surgical patients are further complicated by albumin losses to wound sites. Even in postoperative patients who have undergone minor surgical procedures (eg simple mastectomy without transfusion) and have relatively normal albumin catabolism, there may be increased movement of albumin from plasma to wound sites yielding third-spaced oedema. It has been estimated that such third-spaced albumin may account for 10%-20% of the estimated catabolism, but the per cent is likely to vary depending on the surgical procedure or extent of thermal injury.
24-29
Serum albumin concentrations reveal little about albumin disposition, particularly in critically ill patients, as concentrations are dependent on a number of factors in addition to any albumin that has been administered ( Table 2) . [30] [31] [32] Similarly, alternatives to radiolabelled albumin that require use of serum albumin concentrations for investigating albumin disposition are fraught with difficulties. For example, mass balance equations using changes in haemoglobin and serum albumin concentrations to estimate albumin distribution half-life require intensive sampling (eg 42 blood samples over an 8-hour period in one study) 33 are based on assumptions about the relationship between haemoglobin and albumin, and do not take into account the return of albumin from lymphatics to circulation. Therefore, radiolabelled albumin remains the gold standard for evaluating the disposition of albumin, although this method has issues that need to be considered when used in critically ill patients. In particular, early intensive blood sampling (eg 8-10 samples in the first hour) is required to characterize initial distribution half-lives due to rapid intravascular to extravascular distribution. Furthermore, extended sampling (eg 4 weeks) is required in patients with disease states such as cirrhosis because albumin exhibits prolonged terminal half-lives compared to normal subjects (25 vs 15 days, respectively). [34] [35] [36] In one highly unlikely disease state, but illustrative of the need for prolonged sampling in certain conditions, a patient with analbuminemia was found to have a terminal half-life of 52 days based on I
125
-labelled albumin sampling.
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A description of the studies beginning in the 1980s of the disposition of albumin in critically ill patients is presented in Table 3 .
38-43 Table 4 is an overview of the limitations of these studies for under- Finally, studies in animal models suggest that only a small concentration of albumin may be necessary to maintain integrity of the endothelial glycocalyx in which case only a small amount of exogenous albumin might be needed for clinical effectiveness. 46 Such animal data have been used as a justification for maintaining physiologic concentrations of albumin the blood of critically ill patients, 47 but the relationship between albumin concentrations and fluid escape in the critically patient is a function of multiple interacting factors including a host of mediators. 48 
| WHAT IS NE W AND CON CLUS I ON
Knowledge of the disposition of exogenous albumin in critically ill patients is important for understanding its potential effectiveness when titrating its administration based on resuscitation endpoints related to plasma expansion. There is limited but consistent evidence from studies using radiolabelled albumin that albumin administration is likely to have transient effects on plasma expansion due to rapid transcapillary leak in patients undergoing major surgery, patients with at least 40% The mean (range) volume of distribution estimated from the terminal elimination curve was 13 (10-17) L; the initial distribution half-life was 1.1 (0.6-1.5) days; the time to equilibration was 4 (3-7) days; the terminal half-life was 9 (5-11) days; the mean catabolism was 17.1 (8. The mean ± SD amount of fluid infused was 18.6 ± 9.2 mL/kg of saline vs 10.5 ± 5.3 mL/kg of albumin, P < 0.05; change in plasma volume was 4.4 ± 5.6 mL/kg for saline vs 11.0 ± 2.7 mL/kg for albumin, P < 0.05; change in extracellular volume was 16.8 ± 11.7 mL/kg for saline vs 24.8 ± 31.6 mL/kg for albumin, P > 0.05; change in plasma volume/ fluid infusion was 21 ± 24% for saline vs 122 ± 54% for albumin, P < 0.05 No significant differences between saline and albumin groups for mean APACHE II score (16 ± 7 vs 19 ± 8, respectively) or other respiratory and haemodynamic variables at baseline, but wide variation in the changes in fluid volumes within each group after saline or albumin Normal saline or albumin 5% titrated to pulmonary artery occlusion pressure (clinician discretion); 131 I-labelled albumin used to estimate plasma volume and extracellular volume; blood collected before and 20, 30, and 40 min after radiolabelled albumin The mean ± SD amount of fluid infused was 16.6 ± 6 mL/kg of saline vs 8 ± 3 mL/kg of albumin, P < 0.005; change in plasma volume was 2 ± 4 mL/ kg for saline vs 4 ± 7 mL/kg for albumin, P > 0.05; change in extracellular volume was 5 ± 31 mL/kg for saline vs 3 ± 19 mL/kg for albumin, P > 0.05; change in plasma volume/fluid infusion was 9 ± 23% for saline vs 52 ± 84% for albumin, P = 0.05 No significant differences between saline and albumin groups for mean APACHE II score (11 ± 4 vs. 11 ± 3, respectively) or other respiratory and haemodynamic variables at baseline, but wide variation in the changes in fluid volumes within each group after saline or albumin (Continues) thermal injuries and patients with septic shock. Additionally, data from the only study with prolonged blood sampling following radiolabelled albumin administration in critically ill patients suggest that the elimination half-life of exogenous albumin is decreased in more severely ill compared to more stable patient populations. The clinical significance of the latter finding is unknown. More studies evaluating the disposition of albumin in various subsets of critically ill patients are needed to confirm an association between increasing severity of illness and more rapid transcapillary leak and elimination from the body.
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TA B L E 4 Limitations of Studies Examining the Disposition of Albumin in Critically Ill Patients
Radiolabelled albumin is the gold standard for examining the disposition of albumin, but there are inherent limitations when used in critically ill patients that can affect data interpretation Substantial transcapillary escape of albumin can occur during the delayed blood sampling time recommended to ensure adequate mixing of radiolabelled albumin
Only one study had blood sampling beyond 90 min and the patients in that study were not severely ill, so data concerning albumin's catabolism and terminal half-life in critically ill patients are limited
Only one study directly compared the disposition of albumin in healthy subjects and critically ill patients and blood sampling was limited to 60 min, but this study did show that transcapillary escape is more than twice as rapid in patients with septic shock
There is no significant relationship between serum albumin concentrations and indicators of albumin disposition such as transcapillary escape
Apart from patients with septic shock, little is known about the disposition of albumin in subsets of critically ill patients TA B L E 3 (Continued)
